Becton, Dickinson and Company $BDX Shares Sold by Cullen Frost Bankers Inc.

Cullen Frost Bankers Inc. cut its holdings in Becton, Dickinson and Company (NYSE:BDX) by 2.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,209 shares of the medical instruments supplier’s stock after selling 111 shares during the period. Cullen Frost Bankers Inc.’s holdings in Becton, Dickinson and Company were worth $897,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Northcape Wealth Management LLC lifted its holdings in Becton, Dickinson and Company by 0.5% in the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock valued at $2,248,000 after acquiring an additional 51 shares during the last quarter. Diversified Trust Co lifted its holdings in Becton, Dickinson and Company by 4.7% in the first quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock valued at $272,000 after acquiring an additional 53 shares during the last quarter. Bill Few Associates Inc. lifted its holdings in Becton, Dickinson and Company by 0.7% in the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock valued at $1,362,000 after acquiring an additional 55 shares during the last quarter. Meadow Creek Wealth Advisors LLC lifted its holdings in Becton, Dickinson and Company by 5.4% in the first quarter. Meadow Creek Wealth Advisors LLC now owns 1,161 shares of the medical instruments supplier’s stock valued at $266,000 after acquiring an additional 59 shares during the last quarter. Finally, Stephens Inc. AR lifted its holdings in Becton, Dickinson and Company by 0.3% in the first quarter. Stephens Inc. AR now owns 18,578 shares of the medical instruments supplier’s stock valued at $4,255,000 after acquiring an additional 59 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on BDX shares. Morgan Stanley upped their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Finally, Piper Sandler restated a “neutral” rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $205.40.

Becton, Dickinson and Company Stock Down 0.8%

Becton, Dickinson and Company stock opened at $186.62 on Friday. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The stock’s fifty day simple moving average is $190.13 and its 200-day simple moving average is $184.19. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $53.49 billion, a P/E ratio of 33.56, a P/E/G ratio of 1.47 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.32 billion for the quarter. As a group, equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 1,838 shares of company stock worth $348,392 over the last 90 days. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.